Improving CAR T cell therapy using nanoparticles to program virus-specific T cells
Democratizing CAR T cell therapy by in situ programming of virus-specific T cells
This study is looking at a new way to make cancer treatments using your own immune cells more effective and easier to get by using tiny particles that can help program your T cells right in your body, especially for people with multiple myeloma.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10925302 on NIH RePORTER |
What this research studies
This research focuses on enhancing CAR T cell therapy by developing nanoparticles that can program virus-specific T cells directly in the body. The approach aims to simplify and reduce the cost of CAR T cell manufacturing, which currently takes weeks and costs hundreds of thousands of dollars. By utilizing existing influenza vaccinations, the study seeks to boost the effectiveness of CAR T cells against cancers like multiple myeloma. Patients' own T cells will be targeted for modification using these innovative nanoparticles, potentially leading to faster and more accessible treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with hematological malignancies, particularly those who have been vaccinated against influenza.
Not a fit: Patients who do not have hematological cancers or those who are not eligible for CAR T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could make CAR T cell therapy more affordable and widely available for patients with certain types of cancer.
How similar studies have performed: While CAR T cell therapy has been successful in various forms, this specific approach using in situ programming with nanoparticles is novel and has not been widely tested.
Where this research is happening
Atlanta, United States
- Georgia Institute of Technology — Atlanta, United States (Active)
Researchers
- Principal investigator: Su, Fang-Yi — Georgia Institute of Technology
- Study coordinator: Su, Fang-Yi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.